Pegzilarginase Explained

Tradename:	Loargys
Routes Of Administration:	Intravenous
Atc Prefix:	A16
Atc Suffix:	AB24
Legal Eu:	Rx-only
Legal Eu Comment:	^[1] ^[2]
Cas Number:	1659310-95-8
Pubchemsubstance:	405226561
Drugbank:	DB14780
Unii:	4YV4KW88GD
Kegg:	D11695
Synonyms:	AEB-1102
C:	1554
H:	2492
N:	416
O:	463
S:	6

Pegzilarginase, sold under the brand name Loargys, is a medication used for the treatment of hyperargininemia.

The most common side effects include allergic reactions.

Pegzilarginase was approved for medical use in the European Union in December 2023.

Medical uses

Pegzilarginase is indicated for the treatment of arginase 1 deficiency, also known as hyperargininemia.

Society and culture

Legal status

In October 2023, the Committee for Medicinal Products for Human Use adopted a positive opinion, recommending the granting of a marketing authorization under exceptional circumstances for the medicinal product Loargys, intended for the treatment of hyperargininemia. The applicant for this medicinal product is Immedica Pharma AB. Pegzilarginase was approved for medical use in the European Union in December 2023.

Brand names

Pegzilarginase is the international nonproprietary name.^[3]

Pegzilarginase is sold under the brand name Loargys.

External links

• Web site: Pegzilarginase (Code C125143) . NCI Thesaurus . 27 November 2023 . 26 December 2023.

Notes and References

1. Web site: Loargys EPAR . European Medicines Agency . 14 July 2016 . 26 December 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
2. Web site: Loargys Product information . Union Register of medicinal products . 18 December 2023 . 26 December 2023.
3. ((World Health Organization)) . 2018 . International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 79 . WHO Drug Information . 32 . 1 . 10665/330941 . free . World Health Organization .